Medical and Surgical Oncology
It is a special privilege to have Dr Donald Lamm as a coauthor of this section of this issue's Tumor Board. As many of you may recall, Dr Lamm has been a pioneer in the field of bladder cancer treatment since the 1980s. He is best known for his successful work in developing immunotherapy treatment protocols for bladder cancer using bacillus Calmette-Guerin (BCG). He is also well known in the field of integrative medicine as having been the principal investigator of one of best-known trials in nutritional oncology: a trial on the use of high-dose multivitamin supplements in the prevention of bladder cancer recurrence. Dr Lamm discusses this as part of his and Dr Hogan's Tumor Board contribution. We are honored to have an expert of Dr Lamm's caliber and his colleague Dr Hogan collaborate on the medical and surgical oncology approaches to the patient in question in this tumor board.
The first area discussed in detail by Drs Hogan and Lamm is smoking and bladder cancer, a critical issue in this 35 pack-year smoker. Their recommendation that the patient cease smoking crosses the boundaries of conventional and integrative medicine; the datum that up to 70% of bladder cancers are associated with smoking is a stark indictment of this worrisome habit. (This warning will probably not be sufficient to change the patient's smoking habit; research tells us that even if the best science on the disease impact of smoking is carefully presented by the practitioner and understood and believed by a patient, this reasoning will not effectively help a smoker stop smoking. Only if the immediate, albeit small, satisfaction provided by the smoking experience is substituted with another satisfaction will the long-term consequences likely motivate sufficiently to result in actual change.) The issue of susceptible genotypes provides an additional emphasis to the carcinogenic effects of tobacco and appears likely to provide potential future use in estimating risk.
We agree with Hogan and Lamm about the usefulness of positron emission tomograhy (PET) scans in bladder cancer. For the patient with unclear diagnostic parameters, in bladder cancers as well as other cancers, PET can often provide revealing evidence that can be of great clinical value, especially in the detection of metastases. It is peculiar that the use of this diagnostic technique, which has the potential to significantly improve staging of cancers and thereby affect treatment, should be restricted by reimbursement practices when it should optimally be driven instead by informed medical decision making.
Hogan and Lamm provide an excellent surgical review. The discussion of the high risk of recurrence in the ureter stump if it is not removed is important. The type of resection of the ureter and bladder cuff affects the rate of recurrence and metastasis. While the knowledge of this level of surgical detail is usually reserved for specialists, the difference in "downstream" versus "upstream" recurrence patterns in the ureter and bladder is also an important point for all physicians to understand since it dictates the aggressiveness of surgical intervention.
The reduction in the risk of recurrence from a single treatment of intravesical thiotepa is among the valuable clinical pearls in this piece. Another is the personal communication from O'Donnell to the effect that the usefulness of high-dose vitamin supplementation has now been shown in conjunction with BCG and interferon, in addition to the previous work of Lamm with BCG alone. Lamm's high-dose multivitamin trial has received much attention in the area of nutritional oncology, and it is a particular pleasure to read the summary in this contribution. Hogan and Lamm conclude by endorsing the consideration of nutritional and lifestyle measures for this patient, a welcome and understandable acknowledgment of the value of integrative care by these leading clinical and research experts in the field of urological oncology.
Naturopathic Medicine
Dr Eric Yarnell begins his contribution with the summary of diverse treatment strategies that we have come to expect from the naturopathic contributors to this series. The strategies that he outlines include removal of obstacles to cure (lifestyle-based risk reduction), immune augmentation, direct attack on the cancer (differentiation, antiangiogenesis), and reduction of risk of metastasis. Reliance on a suite of treatment strategies of this sort shows that naturopathy is firmly planted in an integrative medical model and is a major reason why we frequently seek out naturopathic contributions to this Tumor Board.
Yarnell cautions against the use of high-dose intravenous vitamin C in bladder cancers on the basis of a reference to the promotion of bladder tumors by sodium ascorbate in laboratory rats. There is in fact a large body of preclinical research showing that sodium ascorbate acts as a promoter in rat models for bladder cancer. Ascorbic acid may act as a copromoter under conditions of increased urinary pH and sodium ion concentration; however, duration of exposure and genetic factors may be critical, and whether one can extrapolate from these models to humans is unclear. Research suggests this is a species-specific effect whereby rats have a unique susceptibility to high-dose sodium L-ascorbate. 1 In contrast, the human oncologic data to date, while more limited, point to favorable outcomes with high-dose ascorbic acid. Early clinical studies by Linus Pauling and colleagues, published as early as 1976 in the Proceedings of the National Academy of Sciences, indicated that intravenous vitamin C had therapeutic effects in patients with advanced bladder cancer, 2 and preliminary reports from Jeanne Drisko and colleagues at the University of Kansas point to promising results with such high-dose regimens in ovarian cancer patients. 3 Vitamin C in doses of 500 mg daily was part of the formulation used in Lamm's trial and was observed to lower recurrence rates in bladder cancer patients as part of this mixedantioxidant formula. While caution is reasonable with vitamin C's contentious history, it is equally possible that such an intervention may turn out to be favorable. Only time and further investigation will tell.
Regarding Yarnell's recommendation for modified citrus pectin, I would concur that the potential benefit is plausible. For the moment, however, the range of cancers possibly affected by its antimetastatic effect is unknown. Evidence to date appears limited to a pilot study of prostate cancer and laboratory studies of prostate cancer, breast cancer, and melanoma.
The recommendation of intravesical administration of methyl glutamine-conjugated γ-linolenic acid (MeGLA), while interesting, may be a bit premature. It is based on the results of a single trial using a compound that does not appear to have been widely studied. While GLA is certainly a well-recognized substance, to date, the conjugated form does not have a strong research background. I would guess that in several areas of the country, it would be difficult to obtain the collaboration of a conventional practitioner to implement the necessary procedures for intravesical administration. It is probably inappropriate to classify this compound as a supplement ( Table 2 in Yarnell's contribution); dietary supplements as defined by federal regulations are oral. Tetrathiomolybdate, similarly, is not a supplement but rather a prescription drug.
Recommendations for use of isoflavone-containing supplements such as soy and kudzu are interesting. The connection of the low rates of bladder cancer in Asia, an area with high smoking rates, to the use of isoflavone-containing foods is an intriguing one to raise and certainly deserves more biological and mechanistic investigation.
Perhaps the most interesting and even startling recommendation in Yarnell's essay was the use of extracts of Catharanthus roseus, Taxus brevifolia, and Cephalotaxus fortunei in the herbal formula. These plants are the sources, respectively, of the vinca alkaloids, taxol, and harringtonine and homoharringtonine (experimental cancer therapeutics).
The major justifications listed for using these plants was their content of cytotoxic antineoplastic drugs plus related compounds that might contribute to a synergistic effect, as well as laboratory reports on the strong anticancer activity of extracts. This raises several questions. Exactly what is absorbed from the tinctures of these plants, especially in the small percentages in which they are found in the formula Yarnell gives? Is enough of the drug absorbed to have significant clinical relevance? The vinca alkaloids were discovered in the traditional herbal remedy Catharanthus, used in many countries around the world. At the time, it was tested in an animal model as an antidiabetic therapy based on its traditional medicine use. It was found to be strongly immunosuppressive, which led to its testing in animal leukemia models and eventually to the discovery of useful anticancer drugs. There remain unknown questions such as, Would any immunosuppressive effect result from use of the tincture? Would this have any clinical relevance? Would any potentially toxic fractions be absorbed from the other species?
To answer the "safety first" questions, we investigated further. The resulting information lessened my concerns about use of these plants. First, such use is not uncommon in the naturopathic profession, at least in the Western United States, where students receive training in the use of plant tinctures as a part of their basic medical education. Second, it appears that all or most of these plants actually do have traditional medicine uses, somewhat allaying concerns about their toxicity when used at a low percentage in an herbal mixture. C roseus is used, as mentioned above, as a diabetes remedy in many countries; it has also been recorded as a cancer treatment in some areas. 4 T brevifolia was widely used by Native Americans for a variety of purposes including "blood purification," strengthening, and wound healing. A 1993 dissertation reported its use for cancer in Canadian indigenous groups. 5 Its close relative Taxus baccata (now used in the supply of the pharmaceutical taxanes) was recognized during the development of the taxanes to be used as a cancer treatment in Ayurvedic medicine. 6 One reference indicates use of C fortunei as an herbal cancer treatment, although it is not widely recognized as an herbal medicine. 7 Interestingly, Camptotheca acuminata (not included in Yarnell's formula), the source of the camptothecins (eg, CPT-11), was originally tested against cancer without knowledge of its ethnobotanical uses; later investigation showed that it was used in traditional Chinese medicine against cancer, especially gastric cancers. I would tend to be critical of human use of any randomly selected plant simply because it happens to have antitumor activity in the laboratory (and there are many of these). But the use of plants that have traditional medicine use plus laboratory evidence of antitumor activity is more easily rationalized, and my concerns with toxicity of low doses of the herbs would tend to be lessened with the background of traditional medicine use. (Do note, however, that while chemotherapies are certainly far more toxic and concerning, agents with low toxicity when used for extended periods without careful supervision can have unforeseen consequences.)
Psychosocial Oncology
This is the first social work perspective that has appeared in the Integrative Tumor Board. Offered by Monica Krise and June Lundy, it begins with a passage that clearly indicates the relationship of social work to the integrative medical model. Terms such as interdisciplinary, systems, and whole person are ones that could just as easily appear in any integrative medical discussion as in this social work discussion. Later in their article, Krise and Lundy make it clear that their commitment at their medical center includes the use of techniques, such as mind-body skills, that we would typically consider as part of integrative medicine.
One of the first topics Krise and Lundy discuss is the value placed in social work on focusing on the strengths of patients in developing a plan of action to assist in coping with and combating cancer. Focusing on the strengths of the individual, they note, is likely to lead to increased feelings of adequacy, worth, and empowerment. This is certainly consistent with our clinical experience in Evanston. One could suggest that building and focusing on strengths is likely among the many reasons for the effectiveness of complementary and integrative treatments in general. Patients learn new patterns and habits that build their strength and confidence by enabling them to take an active role in their treatment, a motivation that is consistently reported in studies that investigate why cancer patients elect to use complementary and integrative medical strategies (including the article by Hann and colleagues in the present issue). 8 The discussion of the correlates of good adjustment in cancer patients mentions the important role of finding meaning in life: it is positively associated with overall good adjustment and inversely correlated with avoidant coping. The importance of finding meaning in life has been discussed by many psychologists and philosophers, among them Victor Frankl, whose work we have considered important in the development of the mind-spirit care program at our center. Krise and Lundy discuss the observation that the patient in question in this Tumor Board is reported as being calm, maintaining a positive attitude, and not experiencing excessive stress about his cancer. Does this represent a patient who has found meaning in life and is surrounded by a good social support network? Or is he constraining and avoiding more difficult emotions as a personal coping strategy or style? Further inquiry is recommended to help determine this; however, we continue to find in our clinic that many patients frequently do not recognize the degree to which they may be exercising avoidance strategies. Our most effective way to find out the dynamics of what patients are experiencing-or denying-has been to go beyond usual clinical and psychological workups by using validated quality-of-life questionnaires administered on a regular basis but in less orthodox ways. These questionnaires have often helped to provide both patients and staff information about personal areas of distress not immediately apparent or acknowledged, so specific interventions can be developed collaboratively with each individual for emotional relief. This can mean fairly simple stressalleviating interventions or else can mean the need for deeper involvement of medical or counseling staff to address significant psychological concerns patients can face-ones that almost invariably accompany lifethreatening illness.
Krise and Lundy also raise other important issues. They mention that there is a lack of information on sexuality in this patient's presented history. It is important to note that this is not included in the Tumor Board cases because of the very personal nature of such information; as part of the psychological record, it is kept separate from the rest of the patient's case history to protect the patient's privacy. They also mention the importance of spousal distress or calm for cancer patients. It is certainly true that the anxious patient may be grounded by a calm and supportive spouse or other family member; it is just as true that anxious family members can destabilize the adjustment of a patient. Adequate psychological care of the spouse is thus of great importance in psychosocial oncology.
It is encouraging to see an accelerated growth in the implementation of mind-body programs in medical centers that have been discussed in the pages of this journal. Also, patients now have a network of referral possibilities including dietetics, naturopathy, experts in exercise physiology, pain management, and social work. As to the care of mind, emotions, and spirit, there are a number of useful programs that are focused on mindfulness-based stress reduction, hypnosis, guided imagery, and programs based on the work of many well-known and widely published researchers such as Lydia Temoshok, Alastair Cunningham, and Michael Antoni and colleagues. Advances in mind-spirit care have much to contribute to the welfare of cancer patients. Whether such care ultimately changes survival is yet to be determined. Importantly, however, such interventions can transform the distress cancer patients face at a time when any surcease is much needed.
